Get the Stockscreener App
73.07
2.47%
-1.85
After Hours:
72.65
-0.42
-0.57%
Crispr Therapeutics Ag stock is traded at $73.07, with a volume of 3.80M.
It is down -2.47% in the last 24 hours and up +41.03% over the past month.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
See More
Previous Close:
$74.92
Open:
$77.33
24h Volume:
3.80M
Relative Volume:
1.33
Market Cap:
$6.65B
Revenue:
$170.10M
Net Income/Loss:
$-239.59M
P/E Ratio:
-26.10
EPS:
-2.8
Net Cash Flow:
$-191.20M
1W Performance:
+7.87%
1M Performance:
+41.03%
6M Performance:
+113.28%
1Y Performance:
+60.98%
1-Day Range:
$70.30
$78.00
1-Week Range:
$67.38
$78.48
52-Week Range:
$30.04
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Name
Crispr Therapeutics Ag
Sector
Industry
Phone
(617) 315-4600
Address
BAARERSTRASSE 14, ZUG
Compare CRSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
73.07 | 6.81B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | JP Morgan | Overweight |
| Feb-14-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-12-25 | Upgrade | TD Cowen | Sell → Hold |
| Feb-03-25 | Initiated | H.C. Wainwright | Buy |
| Aug-06-24 | Reiterated | Needham | Buy |
| Aug-02-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-28-24 | Resumed | Guggenheim | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-11-23 | Downgrade | TD Cowen | Market Perform → Underperform |
| Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-27-23 | Initiated | Mizuho | Buy |
| Aug-17-23 | Upgrade | Citigroup | Neutral → Buy |
| May-30-23 | Initiated | William Blair | Outperform |
| Apr-13-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Mar-17-23 | Initiated | Bryan Garnier | Buy |
| Mar-07-23 | Initiated | Robert W. Baird | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Underweight |
| Aug-09-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-23-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Upgrade | Citigroup | Sell → Neutral |
| Apr-21-21 | Upgrade | Jefferies | Hold → Buy |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-10-20 | Reiterated | Chardan Capital Markets | Buy |
| Dec-10-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-10-20 | Reiterated | Needham | Buy |
| Dec-07-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Jul-28-20 | Reiterated | Needham | Buy |
| Jul-14-20 | Initiated | SunTrust | Buy |
| Jun-15-20 | Reiterated | Canaccord Genuity | Buy |
| Mar-05-20 | Initiated | Stifel | Hold |
| Feb-03-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-19-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Nov-12-19 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-01-19 | Initiated | Jefferies | Buy |
| Jul-26-19 | Initiated | Canaccord Genuity | Buy |
| Jun-10-19 | Initiated | ROTH Capital | Buy |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-14-19 | Initiated | William Blair | Mkt Perform |
| Jan-28-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-22-19 | Downgrade | Citigroup | Neutral → Sell |
View All
Crispr Therapeutics Ag Stock (CRSP) Latest News
Analyzing net buyer seller activity in CRISPR Therapeutics AGTrade Signal Summary & Weekly High Conviction Trade Ideas - newser.com
CRISPR Therapeutics AG stock retracement – recovery analysisMarket Sentiment Review & Long-Term Capital Growth Strategies - newser.com
Measuring CRISPR Therapeutics AG’s beta against major indicesJuly 2025 Levels & Real-Time Stock Entry Alerts - newser.com
Can Owais Metal and Mineral Processing Limited Compete Against Disruptor Stocks in Its SectorStraddle and Strangle Trades & Free Stay Ahead With Picks - earlytimes.in
CRISPR Therapeutics' (CRSP) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
4,245 Shares in CRISPR Therapeutics AG $CRSP Bought by Valeo Financial Advisors LLC - MarketBeat
Crispr Therapeutics AG: Buy Rating Backed by Innovative SyNTase Platform and Promising Preclinical Data - TipRanks
CRISPR Therapeutics AG Hits New 52-Week High of $78.47 - Markets Mojo
CRSP: Needham Reiterates Buy Rating with $81 Target Price | CRSP Stock News - GuruFocus
Crispr Therapeutics AG: Promising Advancements in Gene Editing Justify Buy Rating - TipRanks
CRISPR Therapeutics (NASDAQ:CRSP) Reaches New 12-Month HighShould You Buy? - MarketBeat
CRSP Showcases Promising Preclinical Data for AATD Treatment - GuruFocus
CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform - The Manila Times
CRISPR Therapeutics Highlights Potential Best-in-Class AATD Treatment with CTX460 at ESGCT 2025 Annual Congress - Quiver Quantitative
CRISPR Therapeutics Presents New Preclinical Data for - GlobeNewswire
>90% mRNA correction: CRISPR Therapeutics' CTX460 raises serum AAT >5-fold and shows durable in vivo editing - Stock Titan
Combining machine learning predictions for CRISPR Therapeutics AG2025 EndofYear Setup & Community Consensus Stock Picks - newser.com
McElhenny Sheffield Capital Management LLC Invests $6.62 Million in CRISPR Therapeutics AG $CRSP - MarketBeat
Crispr Therapeutics: This Cheap Stock to Buy Is Up 65% in 2025 - Morningstar
Multi factor analysis applied to CRISPR Therapeutics AG2025 Key Highlights & High Return Stock Watch Alerts - newser.com
CRISPR Therapeutics (NASDAQ:CRSP) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results - ADVFN
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
CRISPR Therapeutics Hits Day High with 8.72% Surge in Stock Price - Markets Mojo
CRISPR Therapeutics AG Hits New 52-Week High of $73.95 - Markets Mojo
Tempus AI and CRISPR Therapeutics: The Twin Engines of Precision Medicine - Tokenist
Published on: 2025-10-09 06:29:21 - newser.com
Is CRISPR Therapeutics AG trending in predictive chart models2025 Major Catalysts & Real-Time Price Movement Reports - newser.com
CRISPR Therapeutics (CRSP) Surges 8.7%: Is This an Indication of Further Gains? - Nasdaq
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 9.5%Time to Buy? - MarketBeat
CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside - ts2.tech
Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead - The Globe and Mail
Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead - The Motley Fool
Tyche Wealth Partners LLC Increases Position in CRISPR Therapeutics AG $CRSP - MarketBeat
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock - sharewise.com
Slow Capital Inc. Purchases 10,152 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Capital Advisors Inc. OK Sells 300,506 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics AG stock outlook for YEARWeekly Market Outlook & Free Weekly Watchlist of Top Performers - newser.com
What valuation ratios show for CRISPR Therapeutics AG (1CG) stockEarnings Risk Report & AI Powered Trade Plan Recommendations - newser.com
Leading vs lagging indicators on CRISPR Therapeutics AG performanceMarket Sentiment Summary & High Conviction Buy Zone Picks - newser.com
Does CRISPR Therapeutics' (CRSP) SyNTase Spotlight Signal Durable Leadership in Genetic Medicine Innovation? - simplywall.st
What candlestick patterns are forming on CRISPR Therapeutics AGJuly 2025 Closing Moves & Stepwise Trade Execution Plans - newser.com
Does CRISPR Therapeutics AG qualify in momentum factor screening2025 Price Targets & Safe Entry Trade Signal Reports - newser.com
IVC Wealth Advisors LLC Makes New Investment in CRISPR Therapeutics AG $CRSP - MarketBeat
Alta Wealth Advisors LLC Takes Position in CRISPR Therapeutics AG $CRSP - MarketBeat
Order flow analysis tools used on CRISPR Therapeutics AG2025 Big Picture & Reliable Intraday Trade Plans - newser.com
Published on: 2025-10-05 05:03:09 - newser.com
Published on: 2025-10-05 03:39:23 - newser.com
Relative strength of CRISPR Therapeutics AG in sector analysisMarket Weekly Review & Expert Curated Trade Ideas - newser.com
CRISPR Therapeutics (NASDAQ:CRSP) Hits New 12-Month High – What’s Next? - Defense World
CRISPR Therapeutics AG Stock Analysis and ForecastCapital Gains Strategies & Minimal Capital Growth Plans - earlytimes.in
Crispr Therapeutics Ag Stock (CRSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Crispr Therapeutics Ag Stock (CRSP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Treco Douglas A | Director |
Aug 06 '25 |
Buy |
57.03 |
20,000 |
1,140,600 |
22,000 |
| George Simeon | Director |
Jul 16 '25 |
Buy |
52.03 |
989,812 |
51,499,918 |
1,730,179 |
| Patel Naimish | Chief Medical Officer |
May 29 '25 |
Sale |
35.94 |
3,932 |
141,316 |
6,068 |
| Kulkarni Samarth | Chief Executive Officer |
Mar 21 '25 |
Sale |
41.23 |
10,031 |
413,578 |
195,085 |
| Bruno Julianne | Chief Operating Officer |
Mar 21 '25 |
Sale |
41.23 |
1,714 |
70,668 |
10,544 |
| Prasad Raju | Chief Financial Officer |
Mar 21 '25 |
Sale |
41.23 |
2,197 |
90,582 |
16,767 |
| KASINGER JAMES R. | General Counsel and Secretary |
Mar 21 '25 |
Sale |
41.23 |
3,185 |
131,318 |
81,729 |
| Prasad Raju | Chief Financial Officer |
Mar 17 '25 |
Sale |
41.80 |
3,762 |
157,252 |
12,714 |
| Kulkarni Samarth | Chief Executive Officer |
Mar 11 '25 |
Sale |
42.42 |
9,973 |
423,055 |
180,890 |
| Kulkarni Samarth | Chief Executive Officer |
Mar 12 '25 |
Sale |
43.32 |
4,462 |
193,294 |
185,428 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):